Show simple item record

dc.contributor.authorYin, Y
dc.contributor.authorLi, R
dc.contributor.authorXu, K
dc.contributor.authorDing, S
dc.contributor.authorLi, J
dc.contributor.authorBaek, G
dc.contributor.authorRamanand, SG
dc.contributor.authorDing, S
dc.contributor.authorLiu, Z
dc.contributor.authorGao, Y
dc.contributor.authorKanchwala, MS
dc.contributor.authorLi, X
dc.contributor.authorHutchinson, R
dc.contributor.authorLiu, X
dc.contributor.authorWoldu, SL
dc.contributor.authorXing, C
dc.contributor.authorDesai, NB
dc.contributor.authorFeng, FY
dc.contributor.authorBurma, S
dc.contributor.authorde Bono, JS
dc.contributor.authorDehm, SM
dc.contributor.authorMani, RS
dc.contributor.authorChen, BPC
dc.contributor.authorRaj, GV
dc.date.accessioned2017-08-14T13:38:44Z
dc.date.issued2017-09-15
dc.identifier.citationCancer research, 2017, 77 (18), pp. 4745 - 4754
dc.identifier.issn0008-5472
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/771
dc.identifier.eissn1538-7445
dc.identifier.doi10.1158/0008-5472.can-17-0164
dc.description.abstractIn prostate cancer, androgen deprivation therapy (ADT) enhances the cytotoxic effects of radiotherapy. This effect is associated with weakening of the DNA damage response (DDR) normally supported by the androgen receptor. As a significant number of patients will fail combined ADT and radiotherapy, we hypothesized that DDR may be driven by androgen receptor splice variants (ARV) induced by ADT. Investigating this hypothesis, we found that ARVs increase the clonogenic survival of prostate cancer cells after irradiation in an ADT-independent manner. Notably, prostate cancer cell irradiation triggers binding of ARV to the catalytic subunit of the critical DNA repair kinase DNA-PK. Pharmacologic inhibition of DNA-PKc blocked this interaction, increased DNA damage, and elevated prostate cancer cell death after irradiation. Our findings provide a mechanistic rationale for therapeutic targeting of DNA-PK in the context of combined ADT and radiotherapy as a strategy to radiosensitize clinically localized prostate cancer. Cancer Res; 77(18); 4745-54. ©2017 AACR.
dc.formatPrint-Electronic
dc.format.extent4745 - 4754
dc.languageeng
dc.language.isoeng
dc.publisherAMER ASSOC CANCER RESEARCH
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectTumor Cells, Cultured
dc.subjectAnimals
dc.subjectHumans
dc.subjectMice
dc.subjectMice, Nude
dc.subjectProstatic Neoplasms
dc.subjectPhenylthiohydantoin
dc.subjectAndrogen Antagonists
dc.subjectReceptors, Androgen
dc.subjectAntineoplastic Agents
dc.subjectProtein Kinase Inhibitors
dc.subjectXenograft Model Antitumor Assays
dc.subjectDNA Repair
dc.subjectRadiation, Ionizing
dc.subjectMale
dc.subjectDNA-Activated Protein Kinase
dc.titleAndrogen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation.
dc.typeJournal Article
dcterms.dateAccepted2017-07-20
rioxxterms.funderThe Institute of Cancer Research
rioxxterms.identifier.projectUnspecified
rioxxterms.versionofrecord10.1158/0008-5472.can-17-0164
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancer research
pubs.issue18
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume77
pubs.embargo.terms12 months
icr.researchteamProstate Cancer Targeted Therapy Group
dc.contributor.icrauthorDe Bono, Johann


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record